Four‐year treatment continuation rates of osteoporosis drugs with different dosing intervals throughout Japan
Introduction There are approximately 13 million patients with osteoporosis in Japan; however, only 20% of them receive treatment. This study compared the 4‐year continuation rates of osteoporosis drugs at different dosing intervals across throughout Japan. Materials and methods Receipt data were ana...
Gespeichert in:
| Veröffentlicht in: | Geriatrics & gerontology international 2023-09, Vol.23 (9), p.665-670 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 670 |
|---|---|
| container_issue | 9 |
| container_start_page | 665 |
| container_title | Geriatrics & gerontology international |
| container_volume | 23 |
| creator | Idei, Koichi Ryu, Kazuteru Miura, Seiji Hiraga, Kenichi Hayama, Yohsuke Suzuki, Arata Okubo, Naoki Arai, Yuji Takahashi, Kenji |
| description | Introduction
There are approximately 13 million patients with osteoporosis in Japan; however, only 20% of them receive treatment. This study compared the 4‐year continuation rates of osteoporosis drugs at different dosing intervals across throughout Japan.
Materials and methods
Receipt data were analyzed to determine the continuation of osteoporosis medication in patients who began treatment at 210 hospitals throughout Japan between October 2016 and September 2017. Continuation rates were compared using Kaplan–Meier curves and log‐rank tests.
Results
The 4‐year continuation rates of daily, weekly, monthly, semi‐annual, and yearly medications nationwide were 8.6%, 16.5%, 13.5%, 31.0%, and 26.0%, respectively. The 4‐year continuation rates for semi‐annual and yearly drugs were significantly higher than daily, weekly, monthly drugs.
Conclusion
Throughout Japan, the 4‐year treatment continuation rates of daily, weekly, monthly, semi‐annual, and yearly osteoporosis drugs all decreased over time. However, the continuation rates of semi‐annual and yearly drugs in the fourth year were significantly higher than those for the other dosing regimens. Therefore, injectable drugs with dosing intervals ≥6 months may improve continuation rates of osteoporosis drugs. Geriatr Gerontol Int 2023; 23: 665–670.
In various regions of Japan, the 4‐year treatment continuation rates of daily, weekly, monthly, semi‐annual, and yearly drugs of osteoporosis drugs with different dosing intervals decreased over time. However, the continuation rates of semi‐annual and yearly drugs in the fourth year were significantly higher than those of the other drugs. |
| doi_str_mv | 10.1111/ggi.14641 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2838646791</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2838646791</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3371-c1f2dcb53ffb535ec7123db16adb5057954c27fdf5717d6091dec5237694fe023</originalsourceid><addsrcrecordid>eNp1kUFOGzEUhq0KBJSy6AWQpW7oYsBvxh5nliiClAqJDV2PHPt5YpTYwfaAsuMIPULP0qP0JDWEsqiEF7al9_mX9f2EfAZ2CmWdDYM7Bd5y-EAOgHNZMdHxnZc7r0BM2n3yMaU7xkB2AHtkv5FcCAbigNxfhjH-efq5QRVpjqjyCn2mOvjs_KiyC55GlTHRYGlIGcM6xJBcoiaOQ6KPLi-ocdZifH5nysgP1PmM8UEtE_39Ky9iGIdFGDP9rtbKfyK7tkzw6PU8JD8uL26n36rrm9nV9Py60k0jodJga6PnorG2bAK1hLoxc2iVmQsmZCe4rqU1VkiQpmUdGNSibmTbcYusbg7JyTZ3HcP9iCn3K5c0LpfKYxhTX0-aScvbYqSgX_5D74oVX35XqLZYq6EThfq6pXQRkCLafh3dSsVND6x_7qEvPfQvPRT2-DVxnK_QvJH_xBfgbAs8uiVu3k_qZ7OrbeRf1WyVMw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2860172195</pqid></control><display><type>article</type><title>Four‐year treatment continuation rates of osteoporosis drugs with different dosing intervals throughout Japan</title><source>Wiley Online Library All Journals</source><creator>Idei, Koichi ; Ryu, Kazuteru ; Miura, Seiji ; Hiraga, Kenichi ; Hayama, Yohsuke ; Suzuki, Arata ; Okubo, Naoki ; Arai, Yuji ; Takahashi, Kenji</creator><creatorcontrib>Idei, Koichi ; Ryu, Kazuteru ; Miura, Seiji ; Hiraga, Kenichi ; Hayama, Yohsuke ; Suzuki, Arata ; Okubo, Naoki ; Arai, Yuji ; Takahashi, Kenji</creatorcontrib><description>Introduction
There are approximately 13 million patients with osteoporosis in Japan; however, only 20% of them receive treatment. This study compared the 4‐year continuation rates of osteoporosis drugs at different dosing intervals across throughout Japan.
Materials and methods
Receipt data were analyzed to determine the continuation of osteoporosis medication in patients who began treatment at 210 hospitals throughout Japan between October 2016 and September 2017. Continuation rates were compared using Kaplan–Meier curves and log‐rank tests.
Results
The 4‐year continuation rates of daily, weekly, monthly, semi‐annual, and yearly medications nationwide were 8.6%, 16.5%, 13.5%, 31.0%, and 26.0%, respectively. The 4‐year continuation rates for semi‐annual and yearly drugs were significantly higher than daily, weekly, monthly drugs.
Conclusion
Throughout Japan, the 4‐year treatment continuation rates of daily, weekly, monthly, semi‐annual, and yearly osteoporosis drugs all decreased over time. However, the continuation rates of semi‐annual and yearly drugs in the fourth year were significantly higher than those for the other dosing regimens. Therefore, injectable drugs with dosing intervals ≥6 months may improve continuation rates of osteoporosis drugs. Geriatr Gerontol Int 2023; 23: 665–670.
In various regions of Japan, the 4‐year treatment continuation rates of daily, weekly, monthly, semi‐annual, and yearly drugs of osteoporosis drugs with different dosing intervals decreased over time. However, the continuation rates of semi‐annual and yearly drugs in the fourth year were significantly higher than those of the other drugs.</description><identifier>ISSN: 1444-1586</identifier><identifier>EISSN: 1447-0594</identifier><identifier>DOI: 10.1111/ggi.14641</identifier><identifier>PMID: 37455015</identifier><language>eng</language><publisher>Kyoto, Japan: John Wiley & Sons Australia, Ltd</publisher><subject>acute phase reaction ; adherence ; bisphosphonates ; Bone density ; Drug dosages ; Health care access ; Injuries ; Older people ; Osteoporosis ; zoledronic acid</subject><ispartof>Geriatrics & gerontology international, 2023-09, Vol.23 (9), p.665-670</ispartof><rights>2023 Japan Geriatrics Society.</rights><rights>2023 Japan Geriatrics Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3371-c1f2dcb53ffb535ec7123db16adb5057954c27fdf5717d6091dec5237694fe023</cites><orcidid>0000-0002-5925-3737 ; 0000-0001-9405-8462</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fggi.14641$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fggi.14641$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37455015$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Idei, Koichi</creatorcontrib><creatorcontrib>Ryu, Kazuteru</creatorcontrib><creatorcontrib>Miura, Seiji</creatorcontrib><creatorcontrib>Hiraga, Kenichi</creatorcontrib><creatorcontrib>Hayama, Yohsuke</creatorcontrib><creatorcontrib>Suzuki, Arata</creatorcontrib><creatorcontrib>Okubo, Naoki</creatorcontrib><creatorcontrib>Arai, Yuji</creatorcontrib><creatorcontrib>Takahashi, Kenji</creatorcontrib><title>Four‐year treatment continuation rates of osteoporosis drugs with different dosing intervals throughout Japan</title><title>Geriatrics & gerontology international</title><addtitle>Geriatr Gerontol Int</addtitle><description>Introduction
There are approximately 13 million patients with osteoporosis in Japan; however, only 20% of them receive treatment. This study compared the 4‐year continuation rates of osteoporosis drugs at different dosing intervals across throughout Japan.
Materials and methods
Receipt data were analyzed to determine the continuation of osteoporosis medication in patients who began treatment at 210 hospitals throughout Japan between October 2016 and September 2017. Continuation rates were compared using Kaplan–Meier curves and log‐rank tests.
Results
The 4‐year continuation rates of daily, weekly, monthly, semi‐annual, and yearly medications nationwide were 8.6%, 16.5%, 13.5%, 31.0%, and 26.0%, respectively. The 4‐year continuation rates for semi‐annual and yearly drugs were significantly higher than daily, weekly, monthly drugs.
Conclusion
Throughout Japan, the 4‐year treatment continuation rates of daily, weekly, monthly, semi‐annual, and yearly osteoporosis drugs all decreased over time. However, the continuation rates of semi‐annual and yearly drugs in the fourth year were significantly higher than those for the other dosing regimens. Therefore, injectable drugs with dosing intervals ≥6 months may improve continuation rates of osteoporosis drugs. Geriatr Gerontol Int 2023; 23: 665–670.
In various regions of Japan, the 4‐year treatment continuation rates of daily, weekly, monthly, semi‐annual, and yearly drugs of osteoporosis drugs with different dosing intervals decreased over time. However, the continuation rates of semi‐annual and yearly drugs in the fourth year were significantly higher than those of the other drugs.</description><subject>acute phase reaction</subject><subject>adherence</subject><subject>bisphosphonates</subject><subject>Bone density</subject><subject>Drug dosages</subject><subject>Health care access</subject><subject>Injuries</subject><subject>Older people</subject><subject>Osteoporosis</subject><subject>zoledronic acid</subject><issn>1444-1586</issn><issn>1447-0594</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp1kUFOGzEUhq0KBJSy6AWQpW7oYsBvxh5nliiClAqJDV2PHPt5YpTYwfaAsuMIPULP0qP0JDWEsqiEF7al9_mX9f2EfAZ2CmWdDYM7Bd5y-EAOgHNZMdHxnZc7r0BM2n3yMaU7xkB2AHtkv5FcCAbigNxfhjH-efq5QRVpjqjyCn2mOvjs_KiyC55GlTHRYGlIGcM6xJBcoiaOQ6KPLi-ocdZifH5nysgP1PmM8UEtE_39Ky9iGIdFGDP9rtbKfyK7tkzw6PU8JD8uL26n36rrm9nV9Py60k0jodJga6PnorG2bAK1hLoxc2iVmQsmZCe4rqU1VkiQpmUdGNSibmTbcYusbg7JyTZ3HcP9iCn3K5c0LpfKYxhTX0-aScvbYqSgX_5D74oVX35XqLZYq6EThfq6pXQRkCLafh3dSsVND6x_7qEvPfQvPRT2-DVxnK_QvJH_xBfgbAs8uiVu3k_qZ7OrbeRf1WyVMw</recordid><startdate>202309</startdate><enddate>202309</enddate><creator>Idei, Koichi</creator><creator>Ryu, Kazuteru</creator><creator>Miura, Seiji</creator><creator>Hiraga, Kenichi</creator><creator>Hayama, Yohsuke</creator><creator>Suzuki, Arata</creator><creator>Okubo, Naoki</creator><creator>Arai, Yuji</creator><creator>Takahashi, Kenji</creator><general>John Wiley & Sons Australia, Ltd</general><general>Blackwell Publishing Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5925-3737</orcidid><orcidid>https://orcid.org/0000-0001-9405-8462</orcidid></search><sort><creationdate>202309</creationdate><title>Four‐year treatment continuation rates of osteoporosis drugs with different dosing intervals throughout Japan</title><author>Idei, Koichi ; Ryu, Kazuteru ; Miura, Seiji ; Hiraga, Kenichi ; Hayama, Yohsuke ; Suzuki, Arata ; Okubo, Naoki ; Arai, Yuji ; Takahashi, Kenji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3371-c1f2dcb53ffb535ec7123db16adb5057954c27fdf5717d6091dec5237694fe023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>acute phase reaction</topic><topic>adherence</topic><topic>bisphosphonates</topic><topic>Bone density</topic><topic>Drug dosages</topic><topic>Health care access</topic><topic>Injuries</topic><topic>Older people</topic><topic>Osteoporosis</topic><topic>zoledronic acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Idei, Koichi</creatorcontrib><creatorcontrib>Ryu, Kazuteru</creatorcontrib><creatorcontrib>Miura, Seiji</creatorcontrib><creatorcontrib>Hiraga, Kenichi</creatorcontrib><creatorcontrib>Hayama, Yohsuke</creatorcontrib><creatorcontrib>Suzuki, Arata</creatorcontrib><creatorcontrib>Okubo, Naoki</creatorcontrib><creatorcontrib>Arai, Yuji</creatorcontrib><creatorcontrib>Takahashi, Kenji</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Geriatrics & gerontology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Idei, Koichi</au><au>Ryu, Kazuteru</au><au>Miura, Seiji</au><au>Hiraga, Kenichi</au><au>Hayama, Yohsuke</au><au>Suzuki, Arata</au><au>Okubo, Naoki</au><au>Arai, Yuji</au><au>Takahashi, Kenji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Four‐year treatment continuation rates of osteoporosis drugs with different dosing intervals throughout Japan</atitle><jtitle>Geriatrics & gerontology international</jtitle><addtitle>Geriatr Gerontol Int</addtitle><date>2023-09</date><risdate>2023</risdate><volume>23</volume><issue>9</issue><spage>665</spage><epage>670</epage><pages>665-670</pages><issn>1444-1586</issn><eissn>1447-0594</eissn><abstract>Introduction
There are approximately 13 million patients with osteoporosis in Japan; however, only 20% of them receive treatment. This study compared the 4‐year continuation rates of osteoporosis drugs at different dosing intervals across throughout Japan.
Materials and methods
Receipt data were analyzed to determine the continuation of osteoporosis medication in patients who began treatment at 210 hospitals throughout Japan between October 2016 and September 2017. Continuation rates were compared using Kaplan–Meier curves and log‐rank tests.
Results
The 4‐year continuation rates of daily, weekly, monthly, semi‐annual, and yearly medications nationwide were 8.6%, 16.5%, 13.5%, 31.0%, and 26.0%, respectively. The 4‐year continuation rates for semi‐annual and yearly drugs were significantly higher than daily, weekly, monthly drugs.
Conclusion
Throughout Japan, the 4‐year treatment continuation rates of daily, weekly, monthly, semi‐annual, and yearly osteoporosis drugs all decreased over time. However, the continuation rates of semi‐annual and yearly drugs in the fourth year were significantly higher than those for the other dosing regimens. Therefore, injectable drugs with dosing intervals ≥6 months may improve continuation rates of osteoporosis drugs. Geriatr Gerontol Int 2023; 23: 665–670.
In various regions of Japan, the 4‐year treatment continuation rates of daily, weekly, monthly, semi‐annual, and yearly drugs of osteoporosis drugs with different dosing intervals decreased over time. However, the continuation rates of semi‐annual and yearly drugs in the fourth year were significantly higher than those of the other drugs.</abstract><cop>Kyoto, Japan</cop><pub>John Wiley & Sons Australia, Ltd</pub><pmid>37455015</pmid><doi>10.1111/ggi.14641</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-5925-3737</orcidid><orcidid>https://orcid.org/0000-0001-9405-8462</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1444-1586 |
| ispartof | Geriatrics & gerontology international, 2023-09, Vol.23 (9), p.665-670 |
| issn | 1444-1586 1447-0594 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2838646791 |
| source | Wiley Online Library All Journals |
| subjects | acute phase reaction adherence bisphosphonates Bone density Drug dosages Health care access Injuries Older people Osteoporosis zoledronic acid |
| title | Four‐year treatment continuation rates of osteoporosis drugs with different dosing intervals throughout Japan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T09%3A36%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Four%E2%80%90year%20treatment%20continuation%20rates%20of%20osteoporosis%20drugs%20with%20different%20dosing%20intervals%20%C2%A0throughout%20Japan&rft.jtitle=Geriatrics%20&%20gerontology%20international&rft.au=Idei,%20Koichi&rft.date=2023-09&rft.volume=23&rft.issue=9&rft.spage=665&rft.epage=670&rft.pages=665-670&rft.issn=1444-1586&rft.eissn=1447-0594&rft_id=info:doi/10.1111/ggi.14641&rft_dat=%3Cproquest_cross%3E2838646791%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2860172195&rft_id=info:pmid/37455015&rfr_iscdi=true |